Lupus erythematosus - Lupus Eritematoso
☆ En los resultados de 2022 del Stiftung Warentest de Alemania, la satisfacción del consumidor con ModelDerm fue sólo ligeramente inferior que con las consultas de telemedicina pagadas.
Aparece como un eritema ligeramente violáceo.
La erupción en forma de mariposa que suele aparecer en la cara.
relevance score : -100.0%
ReferencesIdentificar y clasificar cutaneous lupus erythematosus (CLE) plantea desafíos diagnósticos, distinguiéndolo del systemic lupus erythematosus con afectación cutánea. Estudios recientes arrojan luz sobre los factores genéticos, ambientales e inmunológicos que subyacen al CLE. En particular, la inducción por fármacos se ha convertido en uno de los desencadenantes más importantes del CLE. El tratamiento incluye terapias tópicas y sistémicas, entre ellas productos biológicos prometedores, como belimumab, rituximab, ustekinumab, anifrolumab y BIIB059, con eficacia demostrada en ensayos clínicos.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) abarca varios problemas cutáneos, algunos de los cuales pueden estar relacionados con afecciones de salud más amplias. Se clasifica en diferentes tipos, como acute CLE (ACLE), sub‑acute CLE (SCLE) y chronic CLE (CCLE). El CCLE incluye discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus y lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus es un grupo de enfermedades autoinmunes que pueden afectar distintas partes del cuerpo. Algunos tipos, como systemic lupus erythematosus (SLE), afectan a múltiples órganos, mientras que otros, como cutaneous lupus erythematosus (CLE), afectan principalmente a la piel. Se clasifican diferentes subtipos de CLE según una combinación de signos clínicos, examen histológico y análisis de sangre, aunque existe gran variación entre individuos. Los problemas cutáneos suelen desencadenarse por factores como la exposición a la luz solar, el tabaquismo o ciertos medicamentos.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
La causa del lupus eritematoso (lupus erythematosus) no está clara. Entre gemelos idénticos, si uno está afectado existe un 24 % de probabilidad de que el otro también lo esté. También se considera que las hormonas sexuales femeninas, la exposición solar, el tabaquismo, la deficiencia de vitamina D y ciertas infecciones aumentan el riesgo.
Los tratamientos pueden incluir AINE, corticosteroides, inmunosupresores, hydroxychloroquine (hidroxicloroquina) y methotrexate (metotrexato). Aunque los corticosteroides son eficaces, su uso prolongado produce efectos secundarios.